{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:04:12Z","timestamp":1782187452022,"version":"3.54.5"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["21KJB610002"],"award-info":[{"award-number":["21KJB610002"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370136"],"award-info":[{"award-number":["82370136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20210828"],"award-info":[{"award-number":["BK20210828"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20231333"],"award-info":[{"award-number":["BK20231333"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732983"],"award-info":[{"award-number":["2023M732983"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrc.2025.151494","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T21:00:48Z","timestamp":1739653248000},"page":"151494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A mini review on the regulation of coagulation homeostasis through interfering with vitamin K-dependent coagulation\/anticoagulation factors"],"prefix":"10.1016","volume":"753","author":[{"given":"Jiangbo","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-0972","authenticated-orcid":false,"given":"Shixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.151494_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151494_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/hae.14548","article-title":"Acquired bleeding disorders","volume":"28","author":"Tiede","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.bbrc.2025.151494_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1542\/pir.24.3.83","article-title":"Coagulation disorders","volume":"24","author":"Journeycake","year":"2003","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.bbrc.2025.151494_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/foc.2003.15.4.3","article-title":"Spontaneous intracerebral hemorrhage due to coagulation disorders","volume":"15","author":"Quinones-Hinojosa","year":"2003","journal-title":"Neursug. Focus"},{"key":"10.1016\/j.bbrc.2025.151494_bib5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/neurolint15040093","article-title":"Hemorrhagic coagulation disorders and ischemic stroke: how to reconcile both?","volume":"15","author":"Crispino","year":"2023","journal-title":"Neurol. Int."},{"key":"10.1016\/j.bbrc.2025.151494_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)02225-X","article-title":"Blood coagulation","volume":"355","author":"Dahlb\u00e4ck","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151494_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ALN.0000000000002862","article-title":"Maintaining hemostatic balance in treating disseminated intravascular coagulopathy","volume":"131","author":"Brown","year":"2019","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bbrc.2025.151494_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MBC.0000000000000561","article-title":"Haemostatic balance in cirrhosis","volume":"28","author":"Baccouche","year":"2017","journal-title":"Blood Coagul. Fibrin."},{"key":"10.1016\/j.bbrc.2025.151494_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.thromres.2008.08.008","article-title":"Haemostatic profile of full-term, healthy, small for gestational age neonates","volume":"124","author":"Mitsiakos","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1160\/TH15-04-0286","article-title":"Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S","volume":"115","author":"Campello","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2025.151494_bib11","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2025.151494_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4103\/0019-5154.117334","article-title":"Vitamin k deficiency bleeding presenting as nodular purpura in infancy: a rare and life-threatening entity","volume":"58","author":"Gahalaut","year":"2013","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.bbrc.2025.151494_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0083-6729(00)58031-5","article-title":"Vitamin K-dependent proteins","volume":"58","author":"Nelsestuen","year":"2000","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bbrc.2025.151494_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0889-8588(05)70137-4","article-title":"A comprehensive review of vitamin K and vitamin K antagonists","volume":"14","author":"Vermeer","year":"2000","journal-title":"Hematol.\/Oncol. Clin. N."},{"key":"10.1016\/j.bbrc.2025.151494_bib15","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151494_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3329\/fmcj.v13i1.38018","article-title":"A review of warfarin dosing and monitoring","volume":"13","author":"Arif","year":"2018","journal-title":"Faridpur Med. Coll. J."},{"key":"10.1016\/j.bbrc.2025.151494_bib17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM199002153220703","article-title":"Trial of different intensities of anticoagulation in patients with prosthetic heart valves","volume":"322","author":"Saour","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.151494_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(02)07282-3","article-title":"Interpretation of the international normalised ratio in patients with liver disease","volume":"359","author":"Deitcher","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151494_bib19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1592\/phco.2005.25.11.1656","article-title":"Increase in international normalized ratio after smoking cessation in a patient receiving warfarin","volume":"25","author":"Evans","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbrc.2025.151494_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11845-011-0726-0","article-title":"Warfarin anticoagulation: a survey of patients' knowledge of their treatment","volume":"180","author":"Moran","year":"2011","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.bbrc.2025.151494_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"Adcock","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib22","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s00018-008-7565-9","article-title":"Serine peptidases: classification, structure and function","volume":"65","author":"Page","year":"2008","journal-title":"Cellular and Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2025.151494_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1538-7836.2007.02496.x","article-title":"Exosites in the substrate specificity of blood coagulation reactions","volume":"5","author":"Bock","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.bbrc.2025.151494_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.603","article-title":"Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants","volume":"8","author":"Ferro","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bbrc.2025.151494_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2217\/nnm.13.48","article-title":"Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology","volume":"8","author":"Ilinskaya","year":"2013","journal-title":"Nanomedicine-UK"},{"key":"10.1016\/j.bbrc.2025.151494_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/nnm.13.49","article-title":"Nanoparticles and the blood coagulation system. Part II: safety concerns","volume":"8","author":"Ilinskaya","year":"2013","journal-title":"Nanomedicine-UK"},{"key":"10.1016\/j.bbrc.2025.151494_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0083-6729(07)00007-6","article-title":"Vitamin K\u2010dependent carboxylation","volume":"78","author":"Berkner","year":"2008","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bbrc.2025.151494_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/BJ20140130","article-title":"Ca2+ switches the effect of PS-containing membranes on Factor Xa from activating to inhibiting: implications for initiation of blood coagulation","volume":"462","author":"Koklic","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2025.151494_bib29","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/jth.13788","article-title":"Lipid specificity of the membrane binding domain of coagulation factor X","volume":"15","author":"Muller","year":"2017","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.bbrc.2025.151494_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1521-6934(03)00014-2","article-title":"Blood coagulation","volume":"17","author":"Norris","year":"2003","journal-title":"Best Pract. Res. Cl. Ob."},{"key":"10.1016\/j.bbrc.2025.151494_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1043454206298693","article-title":"Theories of blood coagulation, Theories of blood coagulation","volume":"24","author":"Riddel","year":"2007","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"10.1016\/j.bbrc.2025.151494_bib32","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1161\/ATVBAHA.107.155952","article-title":"Intrinsic pathway of coagulation and arterial thrombosis","volume":"27","author":"Gailani","year":"2007","journal-title":"Arterioscl. Throm. Vas."},{"key":"10.1016\/j.bbrc.2025.151494_bib33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscl. Throm. Vas."},{"key":"10.1016\/j.bbrc.2025.151494_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jth.12247","article-title":"Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway","volume":"11","author":"Bouwens","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.bbrc.2025.151494_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2007.06548.x","article-title":"Protein Z\/Z\u2010dependent protease inhibitor (PZ\/ZPI) anticoagulant system and thrombosis","volume":"137","author":"Corral","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2025.151494_bib36","first-page":"1","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Tar."},{"key":"10.1016\/j.bbrc.2025.151494_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2018.1544412","article-title":"Oral small molecules for the treatment of atopic dermatitis: a systematic review","author":"Mobasher","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.bbrc.2025.151494_bib38","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2011-03-345173","article-title":"Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy","volume":"118","author":"Gong","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.151494_bib39","series-title":"Direct Oral Anticoagulants","first-page":"27","article-title":"Pharmacokinetics and pharmacodynamics of DOAC, pharmacokinetics and pharmacodynamics of DOAC","author":"Ferri","year":"2021"},{"key":"10.1016\/j.bbrc.2025.151494_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.12610","article-title":"Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives","volume":"95","author":"Gomez-Outes","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bbrc.2025.151494_bib41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.151494_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbrc.2025.151494_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.thromres.2011.04.011","article-title":"Vitamin K antagonists\u2013current concepts and challenges","volume":"128","author":"Moualla","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MEJ.0000000000000541","article-title":"Vitamin K antagonists and emergencies","volume":"25","author":"Lapostolle","year":"2018","journal-title":"Eur. J. Emerg. Med."},{"key":"10.1016\/j.bbrc.2025.151494_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5482\/ha-12050008","article-title":"Vitamin K antagonists","volume":"32","author":"Steffel","year":"2012","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.bbrc.2025.151494_bib46","first-page":"476","article-title":"Warfarin: indications, risks and drug interactions","volume":"39","author":"Tadros","year":"2010","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.bbrc.2025.151494_bib47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation","volume":"327","author":"Md","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.151494_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bbrc.2025.151494_bib49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2106\/00004623-199709000-00011","article-title":"Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin","volume":"79","author":"Francis","year":"1997","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bbrc.2025.151494_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","article-title":"Disadvantages of VKA and requirements for novel anticoagulants","volume":"26","author":"Shameem","year":"2013","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bbrc.2025.151494_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(02)07282-3","article-title":"Interpretation of the international normalised ratio in patients with liver disease","volume":"359","author":"Deitcher","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151494_bib52","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jcp.2003.008904","article-title":"Warfarin reversal","volume":"57","author":"Hanley","year":"2004","journal-title":"J. Clin. Pathol. (Lond.)"},{"key":"10.1016\/j.bbrc.2025.151494_bib53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/trf.15146","article-title":"Effect of vitamin K administration on rate of warfarin reversal","volume":"59","author":"Polito","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.bbrc.2025.151494_bib54","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH08-04-0116","article-title":"Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon","volume":"100","author":"Beinema","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2025.151494_bib55","series-title":"A Comparison of the Efficacy and Safety of Acenocoumarol and Warfarin in Valve Replaced Patients with Rheumatic Heart Disease","author":"Ray","year":"2019"},{"key":"10.1016\/j.bbrc.2025.151494_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235639","article-title":"Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: a cohort study","volume":"15","author":"van Miert","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.151494_bib57","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/bloodadvances.2017006775","article-title":"VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites","volume":"2","author":"Czogalla","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2025.151494_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.bbrc.2025.151494_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1871525719666210914110750","article-title":"Direct (new) oral anticoagulants (DOACs): drawbacks, bleeding and reversal","volume":"20","author":"Karcioglu","year":"2022","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2025.151494_bib60","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.bbrc.2025.151494_bib61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor Xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib62","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management","volume":"23","author":"Cheung","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2025.151494_bib63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2146\/ajhp110418","article-title":"Apixaban: a novel oral inhibitor of factor Xa","volume":"69","author":"Nutescu","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bbrc.2025.151494_bib64","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","article-title":"Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation: a nationwide cohort study","volume":"49","author":"Yu","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.bbrc.2025.151494_bib65","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/17474086.2016.1256194","article-title":"Betrixaban\u2013the next direct factor Xa inhibitor?","volume":"9","author":"Thoenes","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.bbrc.2025.151494_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.13453","article-title":"The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis","volume":"105","author":"Tao","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bbrc.2025.151494_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/dtb.2019.000013","article-title":"DOAC dosing in renal impairment","volume":"57","author":"Erskine","year":"2019","journal-title":"Drug Therapeut. Bull."},{"key":"10.1016\/j.bbrc.2025.151494_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11239-007-0108-7","article-title":"New oral Xa and IIa inhibitors: updates on clinical trial results","volume":"25","author":"Haas","year":"2008","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.bbrc.2025.151494_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2008-1066023","article-title":"Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa","volume":"34","author":"Harenberg","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bbrc.2025.151494_bib70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","article-title":"Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant","volume":"7","author":"Ganetsky","year":"2011","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.bbrc.2025.151494_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/14779072.5.1.57","article-title":"Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia","volume":"5","author":"Lewis","year":"2007","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.bbrc.2025.151494_bib72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/ALN.0000000000001976","article-title":"Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery","volume":"128","author":"Koster","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bbrc.2025.151494_bib73","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.amjmed.2016.11.029","article-title":"Idarucizumab (Praxbind): the first reversal agent for a direct oral anticoagulant","volume":"130","author":"Finks","year":"2017","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbrc.2025.151494_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HPC.0b013e3182315c03","article-title":"Dabigatran: a review of clinical and pharmacoeconomic evidence","volume":"10","author":"Reddy","year":"2011","journal-title":"Crit. Pathw. Cardiol."},{"key":"10.1016\/j.bbrc.2025.151494_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.aia.0000157499.41843.a3","article-title":"Tifacogin, recombinant tissue factor pathway inhibitor","volume":"43","author":"Matyal","year":"2005","journal-title":"Int. Anesthesiol. Clin."},{"key":"10.1016\/j.bbrc.2025.151494_bib76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.151494_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/13543776.2022.2026926","article-title":"Factor IX (a) inhibitors: an updated patent review (2003-present)","volume":"32","author":"Afosah","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bbrc.2025.151494_bib78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0041-008X(78)90313-7","article-title":"Substituent effects on the hepatotoxicity of thiobenzamide derivatives in the rat","volume":"46","author":"Hanzlik","year":"1978","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151494_bib79","doi-asserted-by":"crossref","first-page":"12782","DOI":"10.1039\/D2CC04420J","article-title":"Chiral nanomaterials for biosensing, bioimaging, and disease therapies","volume":"58","author":"Qu","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbrc.2025.151494_bib80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-021-04243-2","article-title":"Enantiomer-dependent immunological response to chiral nanoparticles","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.151494_bib81","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1039\/D3TB02381H","article-title":"Chiral nanomaterials-based approaches for diagnosis and treatment of protein aggregated neurodiseases: current status and future opportunities","volume":"12","author":"Pranav","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbrc.2025.151494_bib82","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.langmuir.0c01352","article-title":"Regulation of thrombin activity with ultrasmall nanoparticles: effects of surface chemistry","volume":"36","author":"Lira","year":"2020","journal-title":"Langmuir"},{"key":"10.1016\/j.bbrc.2025.151494_bib83","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.chemrestox.2c00190","article-title":"Anionic Ultrasmall gold nanoparticles bind to coagulation factors and disturb Normal hemostatic balance","volume":"35","author":"Lira","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bbrc.2025.151494_bib84","article-title":"Surface functionalization-specific binding of coagulation factors by zinc oxide nanoparticles delays coagulation time and reduces thrombin generation potential in vitro","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.151494_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010952","article-title":"Biocompatibility and cytotoxicity of gold nanoparticles: recent advances in methodologies and regulations","volume":"22","author":"Kus-Li\u015bkiewicz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151494_bib86","doi-asserted-by":"crossref","unstructured":"A. Barman, Review on biocompatibility of ZnO nano particles, in: S. Gupta, S. Bag, K. Ganguly, I. Sarkar, P. Biswas, (eds) Advancements of Medical Electronics. Lecture Notes in Bioengineering. Springer, New Delhi, pp. 343-352, https:\/\/doi.org\/10.1007\/978-81-322-2256-9_32.","DOI":"10.1007\/978-81-322-2256-9_32"},{"key":"10.1016\/j.bbrc.2025.151494_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/iep.12346","article-title":"Experimental models and methods for cutaneous wound healing assessment","volume":"101","author":"Masson\u2010Meyers","year":"2020","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.bbrc.2025.151494_bib88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1067-1927.2004.12601.x","article-title":"Rat models of skin wound healing: a review","volume":"12","author":"Dorsett\u2010Martin","year":"2004","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.bbrc.2025.151494_bib89","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.biomaterials.2009.09.093","article-title":"Enhancement of incisional wound healing by thrombin conjugated iron oxide nanoparticles","volume":"31","author":"Ziv-Polat","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2025.151494_bib90","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jbm.a.32296","article-title":"Synthesis and characterization of recombinant factor VIIa\u2010conjugated magnetic iron oxide nanoparticles for hemophilia treatment","volume":"91","author":"Shafir","year":"2009","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib91","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.biomaterials.2004.10.012","article-title":"Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications","volume":"26","author":"Gupta","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2025.151494_bib92","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/smll.201201531","article-title":"Applications and potential toxicity of magnetic iron oxide nanoparticles","volume":"9","author":"Liu","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.151494_bib93","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.2147\/IJN.S172230","article-title":"Low-molecular-weight sulfonated chitosan as template for anticoagulant nanoparticles","author":"Heise","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.151494_bib94","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/IJN.S355131","article-title":"Nano silver-induced toxicity and associated mechanisms","volume":"17","author":"Zhang","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.151494_bib95","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cclet.2019.11.036","article-title":"Metal-organic framework-based nanomaterials for biomedical applications","volume":"31","author":"Zhang","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bbrc.2025.151494_bib96","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.3390\/s19235260","article-title":"Thrombin aptamer-modified metal\u2013organic framework nanoparticles: functional nanostructures for sensing thrombin and the triggered controlled release of anti-blood clotting drugs","volume":"19","author":"Chen","year":"2019","journal-title":"Sensors-Basel"},{"key":"10.1016\/j.bbrc.2025.151494_bib97","doi-asserted-by":"crossref","first-page":"35574","DOI":"10.1021\/acsami.7b11195","article-title":"Fluorescent thrombin binding aptamer-tagged nanoparticles for an efficient and reversible control of thrombin activity","volume":"9","author":"Riccardi","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbrc.2025.151494_bib98","article-title":"Photothermal nanomaterials for theranostics of atherosclerosis and thrombosis","volume":"35","author":"Vazquez-Prada","year":"2023","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.bbrc.2025.151494_bib99","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1166\/jbn.2012.1416","article-title":"Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles","volume":"8","author":"Wang","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.bbrc.2025.151494_bib100","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/ma11112313","article-title":"Thrombolysis enhancing by magnetic manipulation of Fe3O4 nanoparticles","volume":"11","author":"Li","year":"2018","journal-title":"Materials"},{"key":"10.1016\/j.bbrc.2025.151494_bib101","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nano.2017.12.013","article-title":"Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa","volume":"14","author":"Xia","year":"2018","journal-title":"Nanomed.-Nanotechnol"},{"key":"10.1016\/j.bbrc.2025.151494_bib102","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C8BM00288F","article-title":"Self-assembled, bivalent aptamers on graphene oxide as an efficient anticoagulant","volume":"6","author":"Lai","year":"2018","journal-title":"Biomater. Sci-UK."},{"key":"10.1016\/j.bbrc.2025.151494_bib103","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1039\/C4BM00156G","article-title":"Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: a potent targeted anticoagulant","volume":"2","author":"So","year":"2014","journal-title":"Biomater. Sci-UK."},{"key":"10.1016\/j.bbrc.2025.151494_bib104","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1016\/j.biomaterials.2011.04.059","article-title":"Determinants of the thrombogenic potential of multiwalled carbon nanotubes","volume":"32","author":"Burke","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2025.151494_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ma14205978","article-title":"Biomedical applications of carbon nanomaterials: fullerenes, quantum dots, nanotubes, nanofibers, and graphene","volume":"14","author":"Gaur","year":"2021","journal-title":"Materials"},{"key":"10.1016\/j.bbrc.2025.151494_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2959414","article-title":"Silica nanoparticles effects on blood coagulation proteins and platelets","volume":"2016","author":"Gryshchuk","year":"2016","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.bbrc.2025.151494_bib107","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s12274-021-3394-z","article-title":"Highly efficient artificial blood coagulation shortcut confined on Ca-zeolite surface","volume":"14","author":"Yu","year":"2021","journal-title":"Nano Res."},{"key":"10.1016\/j.bbrc.2025.151494_bib108","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.nano.2011.12.001","article-title":"Polystyrene nanoparticles affecting blood coagulation","volume":"8","author":"Oslakovic","year":"2012","journal-title":"Nanomed.-Nanotechnol."},{"key":"10.1016\/j.bbrc.2025.151494_bib109","doi-asserted-by":"crossref","first-page":"10044","DOI":"10.1021\/ja048548j","article-title":"Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery","volume":"126","author":"Chen","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbrc.2025.151494_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tiv.2019.04.010","article-title":"Generation 2 (G2)\u2013Generation 4 (G4) PAMAM dendrimers disrupt key plasma coagulation parameters","volume":"59","author":"Markowicz-Piasecka","year":"2019","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.bbrc.2025.151494_bib111","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijpharm.2017.01.045","article-title":"Characterization and biocompatibility evaluation of cutaneous formulations containing lipid nanoparticles","volume":"519","author":"Eiras","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.151494_bib112","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2516.2008.01741.x","article-title":"Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes","volume":"14","author":"Yatuv","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.bbrc.2025.151494_bib113","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/17425240903463846","article-title":"Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF","volume":"7","author":"Yatuv","year":"2010","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.bbrc.2025.151494_bib114","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V120.21.2048.2048","article-title":"Oral gene delivery of factor IX Muteins formulated as chitosan nanoparticles for the treatment of hemophilia B","volume":"120","author":"Quade-Lyssy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.151494_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2021.102451","article-title":"What affects the biocompatibility of polymers?","volume":"294","author":"Jurak","year":"2021","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.bbrc.2025.151494_bib116","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1074\/jbc.M314011200","article-title":"Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody","volume":"279","author":"Huang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151494_bib117","doi-asserted-by":"crossref","first-page":"19642","DOI":"10.1016\/S0021-9258(18)41823-6","article-title":"How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X","volume":"267","author":"Selander-Sunnerhagen","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151494_bib118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-385504-6.00002-6","article-title":"Complex assemblies of factors IX and X regulate the initiation, maintenance, and shutdown of blood coagulation","volume":"99","author":"Z\u00f6gg","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.bbrc.2025.151494_bib119","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jth.15793","article-title":"Structural insights into blood coagulation factor VIII: procoagulant complexes, membrane binding, and antibody inhibition","volume":"20","author":"Childers","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.bbrc.2025.151494_bib120","doi-asserted-by":"crossref","first-page":"e1143","DOI":"10.1212\/WNL.0000000000005207","article-title":"Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin","volume":"90","author":"Kurogi","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2025.151494_bib121","first-page":"1","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.151494_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1448","article-title":"The effects of nanomaterials on blood coagulation in hemostasis and thrombosis","volume":"9","author":"Simak","year":"2017","journal-title":"Wires. Nanomed. Nanobi."},{"key":"10.1016\/j.bbrc.2025.151494_bib123","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/smll.201201492","article-title":"Biosafety and bioapplication of nanomaterials by designing protein\u2013nanoparticle interactions","volume":"9","author":"Yang","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.151494_bib124","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","article-title":"Role of computer-aided drug design in modern drug discovery","volume":"38","author":"Macalino","year":"2015","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.bbrc.2025.151494_bib125","article-title":"An overview of nanoparticle protein corona literature","volume":"19","author":"Hajipour","year":"2023","journal-title":"Small"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25002086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25002086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:46:22Z","timestamp":1740743182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25002086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":125,"alternative-id":["S0006291X25002086"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151494","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mini review on the regulation of coagulation homeostasis through interfering with vitamin K-dependent coagulation\/anticoagulation factors","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151494"}}